K36 Therapeutics

Home | K36tx

New York, United States · Founded 2021 · $100.0M raised

Headquarters
New York, New York
Employees
1–10
Founded
2021
Business Model
B2B
Website
k36tx.com
Total Funding
$100.0M
Last Round
$70.0M Series BJun 2023
Rounds
2

About

K36 Therapeutics is a clinical-stage biotech developing KTX-1001 (gintemetostat), a first-in-class oral, selective NSD2/MMSET inhibitor targeting epigenetic drivers of t(4;14) multiple myeloma. The company's lead program is in Phase 1 clinical development, showing target engagement and early clinical activity in relapsed/refractory patients, with a strategy of epigenetic priming to re-sensitize tumors to existing therapies and overcome adaptive resistance.

Summary

K36 Therapeutics is a Biotech company based in New York, United States, founded in 2021. It has raised $100.0M in total across 2 rounds, most recently a $70.0M Series B round in Jun 2023. Investors include F-Prime Capital, Atlas Venture and Eight Roads Ventures.

Tech & App Stack

3 technologies & apps tracked

Every product and vendor across these categories, with where each signal came from.

Create a free account with 25 free credits every month, no card needed, to unlock the full tech & app stack, funding history, and valuations.

Funding History

Sign up to view the funding chart

Create a free account with 25 free credits every month, no card needed, to unlock funding history, valuations, and tech stacks.

Series BSeries BJun 2023
$70.0M

Sign up to see all 2 rounds

Series A through Series B — per-round amounts, valuations, and who invested in each round.

Investors

Similar Companies

Your company? Embed this profile

Add the live badge to your site — it stays current as your funding data updates.

K36 Therapeutics on Indexed.vc
<a href="https://indexed.vc/companies/k36-therapeutics"><img src="https://indexed.vc/api/badge/company/k36-therapeutics" alt="K36 Therapeutics on Indexed.vc" width="260" height="76" /></a>